{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45","value":"474"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"599"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 3 Cmax"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on Day 1 and Day 8 of each 21-day cycle","id":"OG000","title":"Docetaxel + Icrucumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable PK data for Icrucumab and there was no PK data for Docetaxel arm.","reportingStatus":"POSTED","timeFrame":"Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI","title":"PK: Cmax Icrucumab","type":"SECONDARY","unitOfMeasure":"ug/mL"}